Study identification

PURI

https://redirect.ema.europa.eu/resource/19462

EU PAS number

EUPAS13518

Study ID

19462

Official title and acronym

Risk factors for cardiac events in carfilzomib-treated patients in the Marketscan database (20160186)

DARWIN EU® study

No

Study countries

United States

Study description

Descriptive analysis comparing the characteristics of carfilzomib-treated patients who do and do not have claims for a defined cardiac event in the Marketscan administrative claims database. Exploratory objectives will compare incidence of defined cardiac events in carfilzomib-treated patients to multiple myeloma patients not treated with carfilzomib

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Study protocol
Initial protocol
English (634.73 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable